Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
In contrast to previous studies, targeting the mGluR pathway in fragile X syndrome patients did not improve behavior independent of FMR1 methylation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unemployment is high in this population, and even among those employed, individuals are often working below their skills and abilities 220,221 .”
From Autism spectrum disorder (2020) · cites this paper as [221]
In the citing paper
“However, several drug development programs based on the inhibition of mGluR signaling for the treatment of FXS (Novartis and Seaside Therapeutics) were recently closed because efficacy studies in adolescents and adults showed no measurable benefits 114,115 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [114]
In the citing paper
“Exploratory biomarkers and endophenotypes tested in a substudy (n = 56) of the mavoglurant trials suggests an improvement relative to placebo in gaze towards the eye region on an eye-tracking task and in performance on a computerized executive function battery69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
In the citing paper
“Mild side effects (headaches, dizziness, insomnia and vomiting) were observed in about 20% of FXS patients with mavoglurant at higher dose levels69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
In the citing paper
“Conversely, the larger studies of mavoglurant, basimglurant and arbaclofen included over 100 participants and were able to provide conclusions across secondary outcome measures69.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [69]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
Kaufer, D., Cummings, J. L., Ketchel, P., Smith, V. M., MacMillan, A., Shelley, T., López, O. L., & DeKosky, S. T. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.2.233 · Cited by 1,973
Constantino, J. N., Davis, S. A., Todd, R. D., Schindler, M. K., Gross, M. M., Brophy, S. L., Metzger, L. M., Shoushtari, C. S., Splinter, R., & Reich, W. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025014929212 · Cited by 1,611
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
(1985) · PubMed · Cited by 1,427
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Reliability and validity of a computerized neurocognitive test battery, CNS vital signs
GUALTIERI, C., & JOHNSON, L. (2006) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2006.05.007 · Cited by 873 · cited 1×
“CNS VS TheCNSVS is a computerized testing battery focused onworkingmemory; the following four modules were used: Visual Memory Test (VIM), Symbol-Digit Coding (SDC), Perception of Emotions Test (POET), and three-part Continuous Performance Test (CPT) [WorkingMemory Test (WMT)] (31).”
MethodLam, K. S. L., & Aman, M. G. (2007) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0213-z · Cited by 793
Devys, D., Lutz, Y., Rouyer, N., Bellocq, J.-P., & Mandel, J.-L. (1993) · Nature Genetics · doi:10.1038/ng0893-335 · Cited by 780
Manly, T., Anderson, V., Nimmo‐Smith, I., Turner, A., Watson, P., & Robertson, I. H. (2001) · Journal of Child Psychology and Psychiatry · doi:10.1111/1469-7610.00806 · Cited by 693
Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Self-citationThe translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491
Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Fragile X Syndrome: Diagnosis, Treatment, And Research
Silverman, & Cronister, A. (1991) · Johns Hopkins University Press eBooks · Cited by 481
Epidemiology of fragile X syndrome: A systematic review and meta‐analysis
Hunter, J., Rivero‐Arias, O., Angelov, A., Kim, E., Fotheringham, I., & Leal, J. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36511 · Cited by 442
Hagerman, R. J. (2002) · doi:10.56021/9780801868436 · Cited by 299
Self-citationAman, M. G., Wh, B., & WOLFORD, P. L. (1995) · PubMed · Cited by 240
The trouble with spines in fragile X syndrome: density, maturity and plasticity
He, C. X., & Portera-Cailliau, C. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.049 · Cited by 214
Gkogkas, C. G., Khoutorsky, A., Cao, R., Jafarnejad, S. M., Prager-Khoutorsky, M., Giannakas, N., Kaminari, A., Fragkouli, A., Nader, K., Price, T. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.064 · Cited by 201 · cited 1×
“In this respect, better predictors of treatment responsemight include biological indicators of pathway function such as S6 kinase (21), the mRNA 5′ cap–binding protein eukaryotic initiation factor 4E (eIF4E) (22), and matrix metalloproteinase 9 (MMP9) (23) in the periphery, but also markers of central response, such a…”
BackgroundAltered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., Whelan, A. M., Zukin, R. S., Klann, E., & Tassone, F. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00768.x · Cited by 198
Self-citationSansone, S. M., Widaman, K. F., Hall, S. S., Reiss, A. L., Lightbody, A., Kaufmann, W. E., Berry-Kravis, E., Lachiewicz, A., Brown, E. C., & Hessl, D. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1370-2 · Cited by 176
Self-citationHigh MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161 · cited 1×
“In this respect, better predictors of treatment responsemight include biological indicators of pathway function such as S6 kinase (21), the mRNA 5′ cap–binding protein eukaryotic initiation factor 4E (eIF4E) (22), and matrix metalloproteinase 9 (MMP9) (23) in the periphery, but also markers of central response, such a…”
BackgroundSelf-citationAFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome
Levenga, J., Hayashi, S., de Vrij, F. M. S., Koekkoek, S. K. E., van der Linde, H. C., Nieuwenhuizen, I. M., Song, C., Buijsen, R. A. M., Pop, A. S., Gomez‐Mancilla, B., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.022 · Cited by 132
Screening for fragile X syndrome: a literature review and modelling study
Song, F., Barton, P., Sleightholme, V, Yao, G., & Fry-Smith, A. (2003) · Health Technology Assessment · doi:10.3310/hta7160 · Cited by 113
The FMRP regulon: from targets to disease convergence
Fernández, E., Rajan, N., & Bagni, C. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00191 · Cited by 111
Electrocortical changes associated with minocycline treatment in fragile X syndrome
Schneider, A., Leigh, M. J., Adams, P., Nanakul, R., Chechi, T., Olichney, J., Hagerman, R., & Hessl, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494105 · Cited by 108
Self-citationEffectiveness of early intervention for children with Down syndrome
Hines, S. J., & Bennett, F. C. (1996) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/(sici)1098-2779(1996)2:2<96::aid-mrdd7>3.0.co;2-v · Cited by 108
Hagerman, R. J., & Hagerman, P. J. (2002) · Outcomes in Neurodevelopmental and Genetic Disorders · doi:10.1017/cbo9780511543876.009 · Cited by 107
Self-citationAutism spectrum disorders: The quest for genetic syndromes
Zafeiriou, D. I., Ververi, A., Dafoulis, V., Kalyva, E., & Vargiami, E. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32152 · Cited by 107
Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice
Gantois, I., Pop, A. S., de Esch, C. E. F., Buijsen, R. A. M., Pooters, T., Gomez-Mancilla, B., Gasparini, F., Oostra, B. A., D’Hooge, R., & Willemsen, R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.059 · Cited by 100
Exploring the Adult Life of Men and Women With Fragile X Syndrome: Results From a National Survey
Hartley, S. L., Seltzer, M. M., Raspa, M., Olmstead, M., Bishop, E., & Bailey (2011) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-116.1.16 · Cited by 100
Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant
Pop, A. S., Levenga, J., de Esch, C. E. F., Buijsen, R. A. M., Nieuwenhuizen, I. M., Li, T., Isaacs, A., Gasparini, F., Oostra, B. A., & Willemsen, R. (2014) · Psychopharmacology · doi:10.1007/s00213-012-2947-y · Cited by 93
Su, T., Fan, H.-X., Jiang, T., Sun, W.-W., Den, W.-Y., Gao, M.-M., Chen, S.-Q., Zhao, Q.-H., & Yi, Y.-H. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2130-2 · Cited by 76 · cited 1×
“For instance, 2-methyl-6-(phenylethynyl)pyridine (MPEP), a short-acting mGluR5 inhibitor, reduced average neuronal spine length and density at early developmental ages but was less effective in adult mice (20).”
BackgroundThe human trisomy 21 brain: Insights from mouse models of Down syndrome
Holtzman, D. M., Epstein, C. J., & Mobley, W. C. (1996) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/(sici)1098-2779(1996)2:2 · Cited by 7
Research works printed but not linked: 2
- W. Guy in ECDEU Assessment Manual for Psychopharmacology (National Institute of Mental Health Psychopharmacology Research Branch Mental Health Administration Rockville MD 1976) pp. 217–222.
- 10.1176/jnp.12.2.233 · DOI · Paper page
Cited by
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationDevelopmental timing and critical windows for the treatment of psychiatric disorders
Marín, O. (2016) · Nature Medicine · doi:10.1038/nm.4225 · Cited by 374
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
“Moreover, recent results from two large studies failed to demonstrate any efficacy in the primary endpoint, the ABC-C, (Berry-Kravis et al., 2016) (evidence level Ib) regardless of FMR1 methylation status.”
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Self-citation
Metadata
- Authors
- Berry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., Barth, G. M., Jaecklin, T., Apostol, G., & von Raison, F.
- Affiliations
- Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL 60612, USA.
- National Reference Center for Fragile X and Other X-Linked Intellectual Disabilities, CIC 1407 INSERM, Hospices Civils de Lyon, Université de Lyon, 69002 Lyon, France.
- University of California Davis Medical Center (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Assistance Publique – Hôpitaux de Paris (FR)
- Emory University (US)
- Novartis (Germany) (DE)
- Novartis Pharmaceuticals SAS, 92500 Rueil-Malmaison, France.
- Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936–1080, USA.
- Novartis (United States) (US)
- Universitätsklinikum Tübingen (DE)
- Novartis (Switzerland) (CH)
- Neuroscience Development, Novartis Pharma AG, CH-4056 Basel, Switzerland.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-01-13
- Volume
- 8
- Issue
- 321
- Pages
- 321ra5-321ra5
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2237631658
- Cited by
- 270
- References
- 35
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 23 · 2021: 21 · 2020: 35 · 2019: 29 · 2018: 27 · 2017: 54 · 2016: 22
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma AG
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- fragile X syndrome, metabotropic glutamate receptor 5, mGluR5 antagonist, intellectual disability, autism spectrum disorder, behavioral symptoms, synaptic plasticity, drug safety and efficacy
- MeSH terms
- Adolescent, Adult, Age Factors, Behavior, Cognition, Demography, Double-Blind Method, Female, Fragile X Syndrome, Humans, Indoles, Male, Placebos, Least-Squares Analysis, Treatment Outcome, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.